Checkpoint Therapeutics Announces $12 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

H.C. Wainwright & Co. is acting as the exclusive placement agent for the offering. The shares of common stock (or common stock equivalents) described above (but not the unregistered warrants issued in the concurrent private placement or the shares of common stock underlying such unregistered warrants) are being offered by Checkpoint pursuant to a shelf registration statement on Form S-3 (File No. 333- 270843) that was previously filed with the Securities and Exchange Commission ("SEC") on March 24, 2023, an ...